Trial
NCT02289482
A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Infection, Human Immunodeficiency Virus
Intervention
GSK2838232 PIB (SDD)
Why stopped
Study prematurely terminated due to safety concerns leading to clinical hold
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-05-15